IO SEQUENCING Evaluate TMB, MSI and T Cell Repertoire

Tumor foreignness and TCR clonality

Tumor foreignness and TCR clonality

Tumor mutational burden (TMB) and Microsatellite Instability (MSI) are two key components of the IMMUNOGRAM.

Tumors of either high TMB or MSI-high likely harbor neoantigens and may respond more favorably to immunotherapies. These two biomarkers are already widely used to select patients for immunotherapy-based clinical trials.

HalioDx has also developed a TCR clonality test that detects the expansion of T cell clones based on the sequencing of their T cell receptor (TCR).

Such expansion could be indicative of the response to immunotherapy. The test is based on NGS technology and is performed on the same run as tumor foreignness assessment.

 

 

Interested in IO SEQUENCING ? Contact us

 

 

Our IO Scoring Services

HalioDx newsletter subscription


Join our newsletter and be the first to get notified on new updates.


× Hide this popup.